TheraRadar
Clinical-Stage Companies / Dr. Falk Pharma

Dr. Falk Pharma

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 3/1/2025

29
Total Trials
17
Phase 3
11
Phase 2
3
Recruiting
343
Score

Pipeline by Phase

Phase 3
17
Phase 2
11
Phase 1

Therapeutic Focus

Eosinophilic Esophagitis Primary Sclerosing Cholangitis Primary Biliary Cirrhosis Ulcerative Colitis Diverticulitis

Clinical Trials (29)

NCT06596252 Phase 3 RECRUITING

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Started: 5/21/2021

NCT06886360 Phase 3 NOT YET RECRUITING

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

Started: 3/1/2025

NCT03872921 Phase 3 ACTIVE NOT RECRUITING

norUrsodeoxycholic Acid vs Placebo in PSC

Started: 2/8/2018

NCT02493335 Phase 3 COMPLETED

Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis

Started: 1/15/2016

NCT02142634 Phase 3 COMPLETED

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

Started: 5/1/2014

NCT00746486 Phase 3 TERMINATED

Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)

Started: 2/1/2009

NCT02280629 Phase 3 COMPLETED

Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)

Started: 10/1/2014

NCT01208922 Phase 3 COMPLETED

Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea

Started: 11/1/2010

NCT01209208 Phase 3 COMPLETED

Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

Started: 5/1/2010

NCT00695643 Phase 3 TERMINATED

Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

Started: 1/1/2008

NCT01038739 Phase 3 TERMINATED

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

Started: 1/1/2010

NCT02142725 Phase 3 TERMINATED

Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis

Started: 7/21/2014

NCT02434029 Phase 3 COMPLETED

Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis

Started: 11/11/2015

NCT01745770 Phase 3 COMPLETED

TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)

Started: 1/1/2013

NCT00887263 Phase 3 COMPLETED

Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)

Started: 3/1/2009

NCT01278082 Phase 3 COMPLETED

SOIBD Collagenous Colitis Maintenance Study

Started: 4/1/2008

NCT01086553 Phase 3 COMPLETED

9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease

Started: 11/1/2009

NCT07298343 Phase 2 RECRUITING

Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease

Started: 6/10/2024

NCT05621811 Phase 2 COMPLETED

Different Doses of Naronapride vs. Placebo in Gastroparesis

Started: 1/3/2023

NCT05305599 Phase 2 COMPLETED

Different Doses of ZED1227 vs. Placebo in NAFLD

Started: 4/19/2022

NCT05488405 Phase 2 COMPLETED

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Started: 2/9/2023

NCT01966783 Phase 2 COMPLETED

Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis

Started: 9/1/2013

NCT02550418 Phase 2 COMPLETED

Budesonide 9 mg Capsules in Active UC

Started: 10/1/2015

NCT01847664 Phase 2 COMPLETED

Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

Started: 8/1/2013

NCT01755507 Phase 2 COMPLETED

Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis

Started: 12/1/2012

NCT02280616 Phase 2 COMPLETED

Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

Started: 6/1/2011

NCT01279577 Phase 2 COMPLETED

Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease

Started: 11/1/2010

NCT00828230 Phase 2 TERMINATED

Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis

Started: 9/1/2008

NCT01510860 Phase 4 COMPLETED

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Started: 11/1/2008

Drug Candidates

Naronapride Placebo ZED1227 + SIGE Budesonide norucholic acid norUrsodeoxycholic Acid ZED1227 Mesalamine Oral Product Budesonide 0.5mg orodispersible tablet twice daily Budesonide 1mg orodispersible tablet twice daily
Activity Status: Slowing
Last Trial Started: 3/1/2025
Last Trial Ended: 9/4/2025
Trials (12 months): 0
Completed Trials: 20
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.